Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Springer

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Nature Reviews. Cancer|October 19, 2007
Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armouryDouglas Hedley, Lesley Ogilvie, Caroline Springer
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 22, 2013
Bacterial-directed enzyme prodrug therapyPanos Lehouritis, Caroline Springer, Mark Tangney
Pigment Cell & Melanoma Research|January 22, 2010
C-end your drugs using peptide tagsDan Niculescu-Duvaz, Caroline Springer, Richard Marais
Cancer Cell|March 14, 2007
The EGF receptor Hokey-CokeyDan Niculescu-Duvaz, Steven Whittaker, Caroline Springer, et al.
Chembiochem : a European Journal of Chemical Biology|May 3, 2025
Hijacking the MDM2 E3 Ligase with novel BRD4-Targeting PROTACs in Pancreatic Cancer CellsMihaela Ficu, Dan Niculescu-Duvaz, Mohammed Aljarah, et al.
Cancer Research|December 3, 2005
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycinSilvy da Rocha Dias, Frank Friedlos, Yvonne Light, et al.
Cancer Research|October 5, 2006
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signalingNicolas Dumaz, Robert Hayward, Jan Martin, et al.
Journal of Biomolecular Screening|December 20, 2005
Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screenYvette Newbatt, Samantha Burns, Robert Hayward, et al.
Science Translational Medicine|June 12, 2010
Gatekeeper mutations mediate resistance to BRAF-targeted therapiesSteven Whittaker, Ruth Kirk, Robert Hayward, et al.
The Journal of Investigative Dermatology|August 17, 2012
Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinomaAmaya Viros, Robert Hayward, Matthew Martin, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Nature Reviews. Cancer|October 19, 2007
Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armouryDouglas Hedley, Lesley Ogilvie, Caroline Springer
Journal of Controlled Release : Official Journal of the Controlled Release Society|May 22, 2013
Bacterial-directed enzyme prodrug therapyPanos Lehouritis, Caroline Springer, Mark Tangney
Pigment Cell & Melanoma Research|January 22, 2010
C-end your drugs using peptide tagsDan Niculescu-Duvaz, Caroline Springer, Richard Marais
Cancer Cell|March 14, 2007
The EGF receptor Hokey-CokeyDan Niculescu-Duvaz, Steven Whittaker, Caroline Springer, et al.
Chembiochem : a European Journal of Chemical Biology|May 3, 2025
Hijacking the MDM2 E3 Ligase with novel BRD4-Targeting PROTACs in Pancreatic Cancer CellsMihaela Ficu, Dan Niculescu-Duvaz, Mohammed Aljarah, et al.
Cancer Research|December 3, 2005
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycinSilvy da Rocha Dias, Frank Friedlos, Yvonne Light, et al.
Cancer Research|October 5, 2006
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signalingNicolas Dumaz, Robert Hayward, Jan Martin, et al.
Journal of Biomolecular Screening|December 20, 2005
Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screenYvette Newbatt, Samantha Burns, Robert Hayward, et al.
Science Translational Medicine|June 12, 2010
Gatekeeper mutations mediate resistance to BRAF-targeted therapiesSteven Whittaker, Ruth Kirk, Robert Hayward, et al.
The Journal of Investigative Dermatology|August 17, 2012
Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinomaAmaya Viros, Robert Hayward, Matthew Martin, et al.
Pageof 3